Please assess the completion status of the following clinical trial:

Trial Title: Trial of Hydroxychloroquine In Covid-19 Kinetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms occurring within 3 days prior to patient presenting to USA Facility for PCR nasopharyngeal swab~* Nasopharyngeal swab positive for Covid-19 infection and/or exposure and/or symptoms congruent with fever and cough~* Male or Female age 19 to 89 years~* Able to take oral medications~* Patients not requiring hospitalization~* Provision of informed consent~Exclusion Criteria:~* Known history of EKG QTc prolongation abnormality~* Contraindication or allergy to hydroxychloroquine~* Retinal eye disease~* Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency~* Known chronic kidney disease, stage 4 or 5 or receiving dialysis~* Weight \< 40 kg~* Current use of: hydroxychloroquine or cardiac medicines of: flecainide, Tambocor; amiodarone, Cordarone, Pacerone; digoxin or Digox, Digitek, Lanoxin; procainamide or Procan, Procanbid, propafenone, Rythmal)~* Known hepatic disease (cirrhosis, hepatitis)~* Active treatment for cancer (chemotherapy, radiation, surgery within 3 months~* On immunosuppressive drugs steroids, antirejection medications.~* Recipient of solid organ transplant~* Pregnancy/breastfeeding~* Past medical history Porphyria (may exacerbate disease)~* PMH Psoariasis (can worsen disease)~* No access to internet or email~* Current suicidal thoughts according to Columbia scale~* In the screening process before signing consent, subjects will be asked if they are suicidal. If this response is yes, patients will be excluded from trial and directed to the National Suicide Prevention Lifeline: 1-800-273-8255.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Subjects in this arm will receive the study drug
- Placebo (Type: PLACEBO_COMPARATOR): Subjects in this arm will take placebo for 6 days

Based on this trial design, predict the completion outcome and termination type (if applicable).